CClinicalTrials.gg
CompletedNCT05256953Updated Feb 25, 2022

Effect of Bilateral Erector Spinae Plan Block in Colorectal Surgery

An interventional study of Erector spina plane block + general anesthesia and Only general anesthesia in Pain, Postoperative, sponsored by Ondokuz Mayıs University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-02-25.

Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2021, registered Feb 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

In this study, it was aimed to evaluate the effects erector spina plane block (ESPB) on postoperative opioid consumption in the first 24 hours and pain scores after colorectal surgery.

Read the detailed description

Colorectal surgery can be applied for many reasons, among these reasons, colorectal cancer (CRC) takes the first place. With the understanding of the pathophysiological effects of analgesics better, the use of regional techniques in providing analgesia for patients undergoing colorectal cancer surgery has come to the fore. Depending on the surgical procedure, pain faced by patients is an important problem that must be deal with in the postoperative period.

In this study, the hypothesis was determined as "Pre-operatively, erector spina plane block (ESPB) performed as part of multimodal analgesia reduces postoperative morphine consumption and pain scores."

The patients were divided into two groups :

Group ESP (erector spinae plan):

In this group, patients will be administered bilateral ESPB (total of 40 ml, %0.25 bupivacaine) in addition to IV morphine patient-controlled analgesia (PCA) for the first 24 postoperative hours.

Group GA (general anesthesia):

In this group, patients will be administered only IV morphine patient-controlled analgesia (PCA) for the first 24 postoperative hours.

02

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • Regional anesthesia
  • Erector spinae plane block
  • Post-operative analgesia
  • Laparoscopy
  • Open surgery
  • Colorectal surgery
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Ondokuz Mayıs University is the lead sponsor of 262 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged between 18 and 65 years
  • ASA I , II patients
  • BMI\<35 kg/m2 (body weight \<100 kg , >45 kg)
  • Patients who underwent colorectal surgery

Exclusion criteria

Exclusion Criteria:

  • Patients who underwent abdominoperineal resection
  • Patients who were evaluated as unsuccessful block in the dermatomal examination performed after the block was applied.
  • Patients diagnosed with OSAS
  • Pregnancy and breastfeeding
  • Contraindication of regional anesthesia (coagulopathy, abnormal INR, thrombocytopenia, infection at the injection site)
  • Hypersensitivity to local anesthetics or a history of allergy
  • Patients with a history of opioid use longer than four weeks
  • Patients with severe psychiatric diseases such as psychosis or dementia that limit cooperation with the patient.
  • Patients with anatomic deformity ( advanced scoliosis and kyphotic patients. Patients with pectus carinatum and pectus excavatum-like chest deformity )
  • Patients who do not want to participate
  • Patients who have had previous colorectal surgery, excluding diagnostic biopsies
  • Patients who could not be reached by phone to inquire about their pain score at 3rd month.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Group ESP

    bilateral ESPB (total of 40 ml, %0.25 bupivacaine) + IV morphine PCA

    Procedure: Erector spina plane block + general anesthesia

  • Active comparator
    Group GA

    only IV morphine PCA

    Procedure: Only general anesthesia

Interventions

  • ProcedureErector spina plane block + general anesthesia

    Bilateral-injection ultrasound-guided bilateral erector spinae plane block Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally. Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied. Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose. Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day).

    Also known as: Group ESP

  • ProcedureOnly general anesthesia

    Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied. Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose. Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day).

    Also known as: Group GA

06

What researchers measure

Primary outcomes

  1. Postoperative morphine consumption in the first 24 hours

    Morphine consumption in the first 24 hours were measured. Patients will be able to request opioids via a PCA device when their VAS score is above 3 at rest and during activity (coughing and deep breathing).

    Time frame: Postoperative day 1

Secondary outcomes

  1. Postoperative pain scores

    Pain status at rest and while activity (coughing and deep breathing) were assessed by VAS scores at 0, 1, 3, 6, 12, 24 hours and 3th month after extubation. The VAS is an 11 point numeric scale which ranges from 0 to 10 at rest and during activity.

    Time frame: Postoperative month 3

  2. The number of patient requiring rescue analgesia

    The number of patients who required rescue analgesics were recorded at 0, 1, 3, 6, 12 and 24. hours after extubation

    Time frame: Postoperative day 1

  3. Number of patients with postoperative nausea-vomiting and need of antiemetic usage

    The severity of postoperative nausea and vomitting (PONV) was assessed using a descriptive verbal rating scale at 0, 1, 3, 6, 12 and 24 hours after extubation. If a score of 2 or more granisetron 1,5 mg iv will be administered. The PONV scale 0= no nausea, 1= slight nausea 2= moderate nausea, 3= vomiting once, 4= vomiting more than once

    Time frame: Postoperative day 1

  4. Remifentanil consumption during the surgery

    The total amount of remifentanil consumed will be recorded.

    Time frame: The remifentanil consumption will be recorded from anesthesia induction until the patient is referred to the recovery unit, up to 160 min]

  5. Postoperative first oral intake time, first urination, first defecation time, first mobilization time, hospitalization time

    Postoperative first oral intake time, first urination, first defecation time, first mobilization time, hospitalization time were recorded

    Time frame: Postoperative 7 days on an average

  6. Incidence of pruitus

    Number of patient with pruitus were recorded at 0, 1, 3, 6, 12 and 24. hours

    Time frame: Postoperative day 1

07

Study locations

1 site
  • Özgenur Kekül
    Samsun, Other 55200, Turkey
08

References and documents

Publications

  • Chin KJ, El-Boghdadly K. Mechanisms of action of the erector spinae plane (ESP) block: a narrative review. Can J Anaesth. 2021 Mar;68(3):387-408. doi: 10.1007/s12630-020-01875-2. Epub 2021 Jan 6. PubMed 33403545 ↗
  • Tulgar S, Selvi O, Senturk O, Serifsoy TE, Thomas DT. Ultrasound-guided Erector Spinae Plane Block: Indications, Complications, and Effects on Acute and Chronic Pain Based on a Single-center Experience. Cureus. 2019 Jan 2;11(1):e3815. doi: 10.7759/cureus.3815. PubMed 30868029 ↗
  • Forero M, Rajarathinam M, Adhikary S, Chin KJ. Erector spinae plane (ESP) block in the management of post thoracotomy pain syndrome: A case series. Scand J Pain. 2017 Oct;17:325-329. doi: 10.1016/j.sjpain.2017.08.013. Epub 2017 Sep 12. PubMed 28919152 ↗
  • Kendall MC, Alves L, Traill LL, De Oliveira GS. The effect of ultrasound-guided erector spinae plane block on postsurgical pain: a meta-analysis of randomized controlled trials. BMC Anesthesiol. 2020 May 1;20(1):99. doi: 10.1186/s12871-020-01016-8. PubMed 32357842 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05256953
Lead sponsor
Ondokuz Mayıs University
Responsible party
Yasemin Burcu Ustun (Professor, Ondokuz Mayıs University) — Principal investigator
First posted
Feb 25, 2022
Start date
Jan 25, 2021
Primary completion
Mar 1, 2021
Completion
May 1, 2021
Last update
Feb 25, 2022

Study contacts

Yasemin Burcu Üstün, Prof
study director · Ondokuz Mayıs University Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion